ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
ALZ-801 is an orally active small molecule compound that is also an inhibitor of β-amyloid A4 (APP) and a precursor compound of homotaurine, which inhibits the formation of neurotoxic amyloid oligomers, and may be used in studies related to Alzheimer's disease (AD).
ALZ-801 is an orally active small molecule compound that is also an inhibitor of β-amyloid A4 (APP) and a precursor compound of homotaurine, which inhibits the formation of neurotoxic amyloid oligomers, and may be used in studies related to Alzheimer's disease (AD).
ALZ-801 is an orally active small molecule compound that is also an inhibitor of β-amyloid A4 (APP) and a precursor compound of homotaurine, which inhibits the formation of neurotoxic amyloid oligomers, and may be used in studies related to Alzheimer's disease (AD).
ALZ-801 is an orally active small molecule compound that is also an inhibitor of β-amyloid A4 (APP) and a precursor compound of homotaurine, which inhibits the formation of neurotoxic amyloid oligomers, and may be used in studies related to Alzheimer's disease (AD).
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
AM-2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively.